Recombinant adeno-associated virus (rAAV) transduction is limited in vivo, yet can be enhanced by hydroxyurea, ultravioletirradiation, or adenovirus coinfection, possibly via mechanisms involving stress in the host cell. Because chronic ethanol induces oxidative stress, it was hypothesized that chronic ethanol would increase rAAV transduction in vivo. To test this hypothesis, rAAV encoding â€-galactosidase was given to Wistar rats that later received either ethanol diet or high-fat control diet via an enteral-feeding protocol for 3 weeks. Expression and activity of â€-galactosidase in the liver were increased nearly 5-fold by ethanol. The increase in transgene expression was inhibited by antioxidant diphenylene iodonium (DPI), which is consistent with the hypothesis that ethanol causes an increase in rAAV transduction via oxidative stress. Ethanol increased DNA synthesis only slightly; however, it increased the nuclear transcription factor B (NF B) 4-fold, a phenomenon also sensitive to DPI. Moreover, a 6-fold increase in rAAV transgene expression was observed in an acute ischemia-reperfusion model of oxidative stress. Transgene expression was transiently increased 24 hours after ischemia-reperfusion 3 days and 3 weeks after rAAV infection. Further, adenoviral expression of superoxide dismutase or I B⣠superrepressor inhibited rAAV transgene expression caused by ischemia-reperfusion. Therefore, it is concluded that ethanol increases rAAV transgene expression via mechanisms dependent on oxidative stress, and NF B likely through enhancement of cytomegaloviral (CMV) promoter elements. Alcoholic liver disease is an attractive target for gene therapy because consumption of ethanol could theoretically increase expression of therapeutic genes (e.g., superoxide dismutase). Moreover, this study has important implications for rAAV gene therapy and potential enhancement and regulation of transgene expression in liver. (HEPATOLOGY 2000;32:1050-1059.) Adeno-associated virus (AAV)-mediated gene delivery is attractive because it can theoretically provide long-term, stable expression of a transgene. 1,2 Recombinant AAV (rAAV) is also a useful tool for liver-directed gene delivery because the virus can infect nondividing cells, integrate specifically into the host cell genome, and is relatively nonpathogenic compared with more commonly used adenoviral vectors. 1 Although rAAV provides many advantages over other vectors, its transduction efficiency in many tissues, including the liver, is limited either because of the requirement of synthesis of the second strand of DNA in the viral genome 3,4 or because of the lack of transgene expression caused by decreased promoter activity (i.e., inactivation of the cytomegalovirus [CMV] promoter). 5 Second-strand synthesis of the single-stranded AAV viral genome, which is required for the expression of the transgene, is hypothesized to be the limiting step in transduction; however, the cellular mechanisms for this process remain unclear. Various genotoxic agents, such as etoposide and hydroxyu...